Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies [PDF]
International Journal of NanomedicineKehua Jiang,1 Qing Wang,1 Xiao-Long Chen,1 Xiaodong Wang,1 Xiaoya Gu,1 Shuangshuang Feng,1 Jian Wu,2 Haojie Shang,2 Xiaozhuo Ba,2 Yanlong Zhang,1 Kun Tang2 1Department of Urology, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, People’s Republic ...
Jiang K +10 more
doaj +6 more sources
Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors [PDF]
Pharmaceuticals, 2022 Indoleamine 2,3-dioxygenase 1 (IDO1) has received much attention as an immunomodulatory enzyme in the field of cancer immunotherapy. While several IDO1 inhibitors have entered clinical trials, there are currently no IDO1 inhibitor drugs on the market. To
Xixi Hou +4 more
doaj +3 more sources
Synthesis and activity study of novel N,N-diphenylurea derivatives as IDO1 inhibitors [PDF]
Frontiers in Chemistry, 2023 Indoleamine 2,3-dioxygenase 1 (IDO1) has attracted much attention in the field of cancer immunotherapy as an immunomodulatory enzyme. To identify potential IDO1 inhibitors, a novel series of compounds with N,N-diphenylurea and triazole structures were ...
Xi-Xi Hou +10 more
doaj +4 more sources
Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as IDO1 Inhibitors [PDF]
Molecules, 2019 IDO1, a key dioxygenase in tryptophan-kynurenine metabolism, appeared in the last 10 years at the vanguard of druggable targets in cancer therapy due to its well-established role both in immune escape and inflammatory neovascularization.
Marta Serafini +5 more
doaj +4 more sources
Synthesis and Molecular Modeling Studies of N′-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors [PDF]
Molecules, 2017 Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive enzyme that is highly overexpressed in various cancer cells and antigen-presenting cells. It has emerged as an attractive therapeutic target for cancer immunotherapy, which has prompted high ...
Dong-Ho Lee +8 more
doaj +3 more sources
Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors [PDF]
Molecules, 2020 Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme-containing intracellular enzyme that catalyzes the first and rate-determining step of tryptophan metabolism and is an important immunotherapeutic target for the treatment of cancer.
Chuan Zhou +5 more
doaj +3 more sources
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy [PDF]
Journal of Hematology & Oncology, 2021 Indoleamine 2,3-dioxygenase 1 (IDO1) is a heme enzyme that catalyzes the oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune escape via catalyzing the initial step of the kynurenine pathway, and overexpression of IDO1
Kai Tang, Ya-Hong Wu, Yihui Song, Bin Yu
doaj +2 more sources
Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors [PDF]
Frontiers in Pharmacology, 2020 Tumor immunotherapy is considered to be a highlight in cancer treatment in recent years. Indoleamine 2,3-dioxygenase 1 (IDO1) is closely related to the over expression of many cancers, and is therefore a promising target for tumor immunotherapy.
Long-fei Mao +6 more
doaj +2 more sources
Novel 1,2,3-Triazole Erlotinib Derivatives as Potent IDO1 Inhibitors: Design, Drug-Target Interactions Prediction, Synthesis, Biological Evaluation, Molecular Docking and ADME Properties Studies [PDF]
Frontiers in Pharmacology, 2022 Indoleamine 2,3-dioxygenase 1 (IDO1) plays a predominant role in cancer immunotherapy which catalyzes the initial and rate limiting steps of the kynurenine pathway as a key enzyme.
Gui-Qing Xu +9 more
doaj +2 more sources
Molecules, 2020 The discovery of IDO1 and HDAC1 dual inhibitors may provide a novel strategy for cancer treatment by taking advantages of both immunotherapeutic and epigenetic drugs. In this paper, saprorthoquinone (1) and 13 of its analogues from Salvia prionitis Hance
Yang Lin +4 more
doaj +3 more sources